Antibody-mediated marrow failure after allogeneic bone marrow transplantation.
Marrow graft failure observed in association with histocompatibility differences between donor and recipient is often attributed to rejection mediated by host-derived cytolytic T lymphocytes. The data presented in this report indicate that persistent host antibodies specific for donor antigen may also mediate graft failure, either by antibody-dependent cell-mediated cytotoxicity (ADCC), or complement-mediated cytotoxicity. In the case of HLA Class I disparity, where all donor cells express the target antigen, the presence of alpha-donor antibody was associated with complete graft failure and death. In the case of ABO blood group antigen disparity, the presence of alpha-donor antibody resulted in erythroid hypoplasia. The latter cases proved informative insofar as they established that host antibodies could persist for more than 18 months after chemoradiotherapy and impair marrow function.
Barge
A J
AJ
Fred Hutchinson Cancer Research Center, Seattle.
Johnson
G
G
Witherspoon
R
R
Torok-Storb
B
B
D000328:Adult; D000741:Anemia, Aplastic / Q000601:surgery; D000920:Antibody-Dependent Cell Cytotoxicity; D016026:Bone Marrow Transplantation; D003114:Colony-Forming Units Assay; D003602:Cytotoxicity, Immunologic; D005260:Female; D006084:Graft Rejection; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D007938:Leukemia / Q000601:surgery; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous